I-Mab
IMABNASDAQHealthcare
$2.88
$-0.02(-0.69%)
Market Cap$542009454
P/E Ratio—
52W High$6.79
52W Low$0.595
I-Mab (IMAB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMAB · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 13, 2025EPS Actual
-$0.25
Est. -$0.06 · -316.7%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 13, 2025
After Market Close
▼ Miss EPS
IMAB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Apr 1, 2026 | — | — | — | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.06 | -$0.25 | -316.7% | — | — | — |
| ▲ Q3 FY2025 | Aug 20, 2025 | -$0.10 | -$0.07 | +30.0% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.06 | -$0.04 | +33.3% | — | — | — |
| ▲ Q2 FY2025 | Apr 3, 2025 | -$0.01 | -$0.00 | +72.0% | — | $0.00B | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.16 | -$0.25 | -56.3% | — | — | — |
| ▲ Q3 FY2024 | Aug 28, 2024 | -$0.51 | -$0.07 | +86.3% | — | $0.00B | — |
| — Q2 FY2024 | Apr 30, 2024 | — | -$0.26 | — | $0.00B | — | — |
Q2 FY2026
Apr 1, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.25
EPS Est.
-$0.06
EPS Surpr.
-316.7%
Revenue
—
Q3 FY2025
Aug 20, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.10
EPS Surpr.
+30.0%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.06
EPS Surpr.
+33.3%
Revenue
—
Q2 FY2025
Apr 3, 2025Beat
EPS Actual
-$0.00
EPS Est.
-$0.01
EPS Surpr.
+72.0%
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.25
EPS Est.
-$0.16
EPS Surpr.
-56.3%
Revenue
—
Q3 FY2024
Aug 28, 2024Beat
EPS Actual
-$0.07
EPS Est.
-$0.51
EPS Surpr.
+86.3%
Revenue
—
Q2 FY2024
Apr 30, 2024
EPS Actual
-$0.26
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q2 FY2028 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q1 FY2028 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q4 FY2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q3 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q2 FY2027 | $-2.27 | $-2.27 | $-2.27 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 13, 2025 | -316.7% | $4.22 | $4.17 | -1.18% |
| ▲ Q3 FY2025 | Aug 20, 2025 | +30.0% | $4.21 | $4.52 | +7.36% |
| ▲ Q2 FY2025 | May 15, 2025 | +33.3% | $0.88 | $0.89 | +0.31% |
| ▲ Q2 FY2025 | Apr 3, 2025 | +72.0% | $0.78 | $0.73 | -6.19% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -56.3% | $1.04 | $1.07 | +2.88% |
| ▲ Q3 FY2024 | Aug 28, 2024 | +86.3% | $1.26 | $1.17 | -7.14% |
| — Q2 FY2024 | Apr 30, 2024 | — | $1.80 | $1.77 | -1.67% |
| ▲ Q1 FY2024 | Mar 29, 2024 | +116.2% | $1.86 | $1.81 | -2.69% |
Q4 FY2025-1.18%
Report Date
Nov 13, 2025
EPS Beat/Miss
-316.7%
Price Before
$4.22
Price After
$4.17
Q3 FY2025+7.36%
Report Date
Aug 20, 2025
EPS Beat/Miss
+30.0%
Price Before
$4.21
Price After
$4.52
Q2 FY2025+0.31%
Report Date
May 15, 2025
EPS Beat/Miss
+33.3%
Price Before
$0.88
Price After
$0.89
Q2 FY2025-6.19%
Report Date
Apr 3, 2025
EPS Beat/Miss
+72.0%
Price Before
$0.78
Price After
$0.73
Q4 FY2024+2.88%
Report Date
Nov 14, 2024
EPS Beat/Miss
-56.3%
Price Before
$1.04
Price After
$1.07
Q3 FY2024-7.14%
Report Date
Aug 28, 2024
EPS Beat/Miss
+86.3%
Price Before
$1.26
Price After
$1.17
Q2 FY2024-1.67%
Report Date
Apr 30, 2024
EPS Beat/Miss
—
Price Before
$1.80
Price After
$1.77
Q1 FY2024-2.69%
Report Date
Mar 29, 2024
EPS Beat/Miss
+116.2%
Price Before
$1.86
Price After
$1.81
Avg Beat Reaction-1.67%
Avg Miss Reaction+0.85%
Beat Rate5 / 8 quarters
Largest Move+7.36% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMAB ends December
I-Mab (IMAB) most recently reported earnings on November 13, 2025 for Q4 FY2025, posting EPS of $-0.25 — missing the analyst consensus of $-0.06 by -316.7%. The next IMAB earnings date is expected around September 1, 2026.
Each quarter, investors track IMAB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMAB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMAB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMAB earnings · 5 questionsI-Mab's next earnings report is expected around September 1, 2026. IMAB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMAB historically reports after market close (AMC).
IMAB earnings datewhen is IMAB earningsIMAB next earnings datewhen does IMAB report earningsIMAB earnings calendar
▸ Source: FMP · I-Mab SEC filings · US GAAP · I-Mab SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026